Merkel cell carcinoma (MCC) is a rare neuroendocrine malignant neoplasm that most commonly occurs in the head and neck and is rapidly increasing in incidence. The role of adjuvant chemoradiotherapy (CRT) in the management of head and neck MCC remains controversial.
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Merkel cell carcinoma was initially described by Toker in 1972 and called a "trabecular carcinoma of the skin." 2(p107) From 1986 to 2001, the incidence of MCC has increased 3-fold. 3 Merkel cell carcinoma has been shown to be associated with immunosuppression, UV exposure, and mature patient age. 4 Recently, a novel Merkel cell polyomavirus has been detected in MCC tumors, suggesting a viral etiology. 5 The observed increase in incidence of MCC may at least in part be due to the introduction of the cytokeratin-20 stain in 1994, which decreased the likelihood of a missed diagnosis of MCC. 3 In MCC, cytokeratin-20 stains with a characteristic punctate perinuclear pattern. 6 The current management of MCC encompasses a broad range of practices: wide local excision, Mohs surgery, sentinel lymph node biopsy, neck dissection (elective or therapeutic), radiation therapy (RT), chemoradiotherapy (CRT), and chemotherapy (CT). 7 Head and neck MCC has been shown to have unique prognostic factors that differ from those of non-head and neck MCC. 1 There is controversy regarding the role of concurrent CT in patients with MCC who are receiving postoperative RT. 8, 9 The goal of our study was to evaluate the association between CRT and overall survival (OS) in patients with head and neck MCC.
Methods

Data Source and Study Participants
We used the National Cancer Data Base (NCDB) from 1998 to 2011, which encompasses patients from more than 1500 Commission on Cancer accredited programs. 10 Because all patient information is deidentified in the NCDB, our study was granted an exemption by our university institutional review board. The NCDB covers nearly 70% of the incident cases of cancer in the United States.
11
We identified patients with head and neck MCC using the International Classification of Diseases for Oncology, Third Edition, topography codes for skin of the lip (C-44.0), eyelid (C-44.1), external ear (C-44.2), other and unspecified parts of the face (C-44.3), and scalp and neck (C-44.4), and the histology code 8247 (MCC). We included all adult patients (aged ≥18 years) who underwent surgery.
Demographic variables included patient age, sex, race, and comorbidity. Age was categorized into younger than 55, 55 to 64, 65 to 74, and at least 75 years. Race was grouped into white, black, and other. The Charlson/Deyo Comorbidity Score 12 was used to classify comorbidity as 0 (no comorbid conditions), 1, 2 or more comorbidities, and unknown ( Table 1) . Clinical and pathologic variables included surgery type, treatment, tumor size, surgical margins, lymph node status, and pathologic nodal evaluation. Treatment was classified as surgery, adjuvant RT, adjuvant CRT, and adjuvant CT. Tumor size was categorized into less than 2, 2 to less than 3, 3 to less than 4, 4 to less than 5, and 5 cm or greater. Surgical margins were classified into positive margins, negative margins, and unknown. Surgical margins are final margins. Lymph node status was categorized into no positive lymph nodes, positive lymph nodes, and lymph nodes not examined.
Hospital-level variables included hospital type and region. Hospital type was categorized as community, academic, and other cancer programs. Region was grouped into 4 categories: East, South, Midwest, and West.
Our primary outcome of interest was OS. Survival time in years was calculated from the date of diagnosis to death, the last date the patient was known to be alive, or December 31, 2011, whichever came first. Survival data are limited to patients who received a diagnosis from 1998 through 2005.
Statistical Analysis
Bivariate analysis using χ 2 tests was used to analyze categorical variables. Kaplan-Meier analysis was used to analyze survival, and the log-rank test was used to determine statistical significance. Cox proportional hazards regression analysis was used to identify prognostic factors associated with OS, and hazard ratios (HRs) and 95% confidence intervals were calculated for the strength of association. All tests were 2-sided, and P < .05 was considered statistically significant. The analysis was conducted using Statistical Package for the Social Sciences (SPSS) software, version 21.0 (SPSS Inc).
Results
We identified 4815 adult patients with head and neck MCC in the NCDB from 1998 to 2011. The majority of our cohort was male (62.9%) and white (98.1%). A total of 92.0% underwent surgical excision, whereas the remaining 8.0% underwent Mohs surgery. Negative margins were present in 79.1% of the cohort. The 5-year OS rate was 41.3%, the mean (standard error) survival time was 5.50 (0.11) years, and the median (standard error) survival time was 3.41 (0.14) years.
From 1998 to 2011, the proportion of patients who received surgery, adjuvant RT, and adjuvant CRT remained stable ( Figure 1 ). In our cohort, 58.6% of patients with MCC received adjuvant therapy. Most patients who received postoperative therapy had adjuvant RT (82.6%), whereas the remaining patients had either adjuvant CRT (13.9%) or adjuvant CT (3.4%) ( Table 1) . Compared with patients who had adjuvant therapy, those who had surgery alone were more likely to be aged 75 years or older (69.6% vs 61.6%; P < .001), have multiple comorbidities (3.0% vs 4.1%; P = .03), and have negative surgical margins (83.6% vs 76.0%; P < .001).
Five-year OS rates for patients who had surgery alone, adjuvant RT, adjuvant CRT, and adjuvant CT were 38.5%, 42.8%, 47.5%, and 28.7%, respectively (log-rank test, P < .001) (Figure 2 (Table 3) We observed that older age, male sex, and tumors of size 3 cm or greater were associated with decreased survival in head and neck MCC. This validates prior studies that have demonstrated that head and neck MCC has unique prognostic factors that differ from those of MCC in other body sites. head and neck MCC and reported that patients who received postoperative RT had improved local (12% vs 44%; P < .01) and regional (27% vs 85%; P < .01) recurrence rates; there was no significant difference in disease-specific survival (P = .30). For MCC in general, it has been shown that there is a survival benefit for postoperative RT 17, 18 but no difference between postoperative RT and CRT. 9 Hasan et al 9 conducted a systematic review that encompassed 4475 patients with MCC and reported 3-year OS of 56%, 70%, and 73% for patients who underwent surgery, adjuvant RT, and adjuvant CRT, respectively (P < .001). In our subanalysis of only patients who received postoperative therapy, we demonstrated that adjuvant CRT is associated with improved OS over adjuvant RT in patients with certain high-risk characteristics, such as male sex, tumors with positive margins, and tumors of size 3 cm or greater. In the NCDB, there is no centralized review of the pathology by an experienced head and neck pathologist. Other limitations to our study include the absence of survival data for cases diagnosed after 2005, so our cohort for the survival 
Conclusions
Head and neck MCC is a rare and aggressive malignant neoplasm. To our knowledge, our study is the first to examine the role of adjuvant CRT in patients with head and neck MCC, and our findings demonstrate an association between OS and postoperative CRT and RT. Although prior studies have not shown an added survival benefit associated with postoperative CRT over RT, our results suggest that postoperative CRT may be an important tool to use in the management of high-risk patients with head and neck MCC. Further multi-institutional studies are needed to investigate possible systemic treatments and treatment intensification in order to improve outcomes in head and neck MCC. 
